Intech Investment Management LLC Buys New Shares in Design Therapeutics, Inc. (NASDAQ:DSGN)

Intech Investment Management LLC purchased a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,665 shares of the company’s stock, valued at approximately $109,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Paloma Partners Management Co bought a new stake in shares of Design Therapeutics in the 3rd quarter valued at about $64,000. The Manufacturers Life Insurance Company acquired a new position in Design Therapeutics during the third quarter worth approximately $71,000. China Universal Asset Management Co. Ltd. bought a new stake in Design Therapeutics in the fourth quarter valued at approximately $74,000. MetLife Investment Management LLC bought a new stake in Design Therapeutics in the 3rd quarter valued at $104,000. Finally, PDT Partners LLC lifted its stake in shares of Design Therapeutics by 33.1% during the 3rd quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock worth $194,000 after buying an additional 8,972 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Stock Up 1.0 %

Shares of NASDAQ:DSGN opened at $4.19 on Friday. The stock has a market cap of $237.84 million, a PE ratio of -4.93 and a beta of 1.77. Design Therapeutics, Inc. has a 12-month low of $3.15 and a 12-month high of $7.77. The business has a 50 day moving average of $4.71 and a 200-day moving average of $5.34.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Equities research analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.